Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab subcutaneous study in adults with early systemic lupus erythematosus
2023-509146-35-00Phase 4Authorised
- Sponsor
- GSK
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 4, open-label, single-arm trial of belimumab in systemic lupus erythematosus (SLE), sponsored by GSK. Primary endpoint: Achieving lupus low disease activity state at Week 52. Planned start Jan 2025; status: authorised.
02
Drugs
belimumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2023-509146-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509146-35-00.